"The Specify 5-6-5 surgical lead broadens and leverages our extensive portfolio of neuromodulation technology," said Dr. Richard E. Kuntz, president of the Neuromodulation business and senior vice president of Medtronic, Inc. "It represents the latest example of our commitment to developing innovative products with clinically relevant attributes for the treatment of chronic pain and other nervous system disorders."
Chronic pain affects an estimated 75 million people in the United States alone. Medtronic estimates that several million Americans are candidates for treatment with neurostimulation therapy. To date, approximately 200,000 people worldwide have been treated for chronic pain with Medtronic neurostimulation technology.
Ad Statistics
Times Displayed: 109945
Times Visited: 6642 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Medtronic developed and leads the field of neuromodulation, the targeted and regulated delivery of electrical pulses, pharmaceuticals, and biologics to specific sites in the nervous system. The company's Neuromodulation business offers innovative therapies for chronic pain, movement disorders, spasticity, overactive bladder and urinary retention, benign prostatic hyperplasia, and gastroparesis.
Back to HCB News
